79.85 0.00 (0.00%)
After hours: 4:34PM EDT
|Bid||78.00 x 500|
|Ask||80.00 x 700|
|Day's Range||79.40 - 81.80|
|52 Week Range||29.90 - 87.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.60|
CNBC's Meg Tirrell speaks with Troy Cox, Foundation Medicine CEO, discusses how his company is advancing cancer treatment.
Stock Monitor: Miragen Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Foundation Medicine, Inc. (NASDAQ: ...
Foundation Medicine, Inc. today announced that the Centers for Medicare & Medicaid Services issued a final National Coverage Determination for patients who receive next generation sequencing testing with an assay that meets the coverage criteria.
Foundation Medicine, Inc. today announced that Chugai Pharmaceutical Co., Ltd. , one of Japan's leading research-based pharmaceutical companies and a member of the Roche Group, will broaden patient access to Foundation Medicine’s comprehensive genomic profiling services for individuals with advanced cancer.
Foundation Medicine, Inc. and Guardant Health, Inc. announced an agreement to settle false advertising challenges that the companies had filed against each other under the Lanham Act related to advertising for their respective liquid genomic profiling assays.
Foundation Medicine, Inc. today announced that members of the company's management team will present at Cowen & Company’s 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 10:40 a.m.
The Cambridge, Massachusetts-based company said it had a loss of $1.05 per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Foundation Medicine today reported financial and operational results for the fourth quarter and year ended December 31, 2017. Highlights for the quarter and year inclu
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Foundation Medicine, Inc. (NASDAQ: FMI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 4:30 PM Eastern ...
After reading Foundation Medicine Inc’s (NASDAQ:FMI) latest earnings update (30 September 2017), I found it beneficial to look back at how the company has performed in the past and compareRead More...
Foundation Medicine Inc (NASDAQ: FMI ), a manufacturer of genomic analysis diagnostics for solid and circulating cancer, is uniquely positioned in comprehensive cancer profiling, a Cowen analyst said. ...
Foundation Medicine, Inc. today announced that financial results for the company's fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018.
Foundation Medicine, Inc. and the European Organisation for Research and Treatment of Cancer announced today a collaboration in which Foundation Medicine’s comprehensive genomic profiling tests will be used to inform patient eligibility for oncology clinical trials through the EORTC’s Screening Patients for Efficient Clinical Trial Access program.
NEW YORK, Jan. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lands' ...
Foundation Medicine, Inc. today announced that the company has entered into a broad partnership with Pfizer Inc. . The partnership focuses on development, regulatory support and commercialization of companion diagnostics that will be included in updates to FoundationOne CDx™.
Foundation Medicine today announced preliminary unaudited total revenue of approximately $48.9 million for the fourth quarter of 2017 and approximately $152.9 million for the full year ended December 31, 2017, representing a 70% and 31% increase from the $28.8 million and $116.9 million recorded in the fourth quarter and full year ended December 31, 2016, respectively.
Foundation Medicine today announced that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 3:30 p.m.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Foundation Medicine Inc (NASDAQ:FMI) with a market-capitalization of $2.49B, rarely draw their attention and few analysts coverRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Foundation Medicine, Inc. Here are 5 ETFs with the largest exposure to FMI-US. Comparing the performance and risk of Foundation Medicine, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)